Sulzer's Roost
This article was originally published in The Gray Sheet
Executive Summary
Resignation of Ueli Roost as Chairman of Sulzer Medica and of parent firm Sulzer Ltd is effective immediately. A March 26 announcement cites the failure of his proposed reintegration of the two entities last year following shareholder resistance. Succeeding Roost at Sulzer Medica is Max Link, current Sulzer Medica vice-chairman. Link formerly served as CEO of Corange Ltd. and Sandoz Pharma. Leonardo Vannotti will serve as the new chairman of Sulzer Ltd. The firm will seek to prevent election of board members nominated by shareholder InCentive Capital AG at its April 19 annual general meeting to prevent furtherance of an unwelcome takeover attempt. A spin-off of Sulzer Medica is anticipated in the third quarter
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.